Kinase Profiling Inhibitor Database

This is a searchable database of specificities of 243 commonly used signal transduction inhibitors. These results have been provided by the International Centre for Kinase profiling within the MRC Protein Phosphorylation Unit at the University of Dundee.
We strongly recommend undertaking kinase profiling of any kinase inhibitor to be used in a biological experiment. It is essential to have a good feel for the specificity of the kinase inhibitor you are working with in order to be able to properly interpret your data.
If you have additional kinase inhibitors that you would like the International Centre for Kinase profiling team to profile for you please contact us here for further details.
If you have any feedback or suggestions on how to improve this resource we welcome your input. Pass on your ideas to us here.

Inhibitor Structure Image Brutto MW Target Reference Reference 2
Hypothemycin C19H22O8 378.37 cyclin D1 H. Sonoda (1999) Life Sci. 65 381 A. Zhao (1999) J. Antibiot. 52 1086
IC261 C18H17NO4 311.3 CK1 Behrend L. (2000) Oncogene 19 5303 Mashhoon N. (2000) J. Biol. Chem. 275 20052
IKK Inhibitor VII C28H29N5OS 483.6 IKK Waelchli R. (2006) Bioorg. Med. Chem. Lett. 16 108
IKK-2 Inhibitor IV (TPCA-1) C12H10FN3O2S 279.3 IKK2 Podolin P.L. (2005) J. Pharmacol. Exp. Ther. 312 373 Karin M. (2004) Nat. Rev. Drug Discov. 3 17
IKK-2 Inhibitor VIII C21H24N4O2 364.4 IKK2 Murata T. (2004) Bioorg. Med. Chem. Lett. 14 4019
IKK-3 inhibitor IX C22H19N3O5S2 469.5 IKK3 Bamborough P. (2006) Bioorg. Med. Chem. Lett. 16 6236
IMD-0354 C15H8ClF6NO2 383.67 IKK2 Tanaka A, (2005) Blood 105 2324-2331
IPA-3 C20H14O2S2 350.45 PAK1 Deacon S.W. (2008) Chemistry and Biology 15 322
IRAK 1-4 Inhibitor 1 C20H21N5O4 395.41 IRAK1, IRAK4 Powers J. P. (2006) Bioorg. Med. Chem. Lett. 16 2842-2845
IRAK-4 kinase inhibitor a C22H24N4O6 440.45 IRAK4 Wang Z. (2006) Structure 14 1835-1844
IRAK-4 kinase inhibitor b C22H24N4O6 440.45 IRAK4
Ischemin C15H17N3O4S 335.38 p53 CBP Jagat C. Borah (2011) Chemistry & Biology, 18 4 531-541
JNKIN7 C28H27N7O2 493.56 JNK Zhang T. (2012) Chem Biol. 19(1) 140-54
JNKIN8 C29H29N7O2 507.59 JNK Zhang T. (2012) Chem Biol. 19(1) 140-54
K252a C27H21N3O5 467.5 CaMKII Cools J. (2004) Cancer Res. 64 6385 Chin L.S. (1999) Cancer Invest. 17 391
Kalopanaxsaponin A C41H66O12 750.96
Kenpaullone C16H11BrN2O 327.2 GSK, CDK Bain J. (2003) Biochem. J. 371 199 Buolamwini J.K. (2000) Curr. Pharm. Des. 6 379
KIN 112 C32H36N6O4 568.67 Lck Martin M.W. (2006) J.Med.Chem. 49 4981-4991
KN62 C38H35N5O6S2 721.9 CaMKII Minami H. (1994) Biochem. Biophys. Res. Commun. 199 241
KN93 C26H29CIN2O4S 501 CaMKII Fan G.H. (1999) Mol. Pharmacol. 56 39 Tombes R.M. (1995) Cell Growth Differ. 6 1063
KT5720 C32H31N3O5 537.6 PKA Simpson CS. Morris BJ. (1995) Neuroscience 68 97-106 Cabell L. Audesirk G. (1993) Int. J. Dev. Neurosci. 11 357
KU 0063794 C25H31N5O4 465.54 mTOR Juan M. García-Martínez (2009) Biochem J. 421 29–42
KU 55933 C21H17NO3S2 395.49 ATM kinase Hickson (2004) Cancer Res. 64 9152
KU55933 C21H17NO3S2 395.49 ATM Li Y. (2010) Mol. Cancer Ther. 2010 Jan. 9(1) 113-25
LDN-193189 C25H22N6 406.49 BMP Yu (2008) Nat. Chem. Biol. 4 33–41 Cuny (2008) Bioorg. Med. Chem. Lett. 18 4388–4392
Leflunomide C12H9F3N2O2 270.20727
Lenalidomide (Revlimid) C13H13N3O3 259.26 TNF-α Rushworth S.A. (2013) Cellular Signalling 25 1 106-112
LFM-A13 C11H8Br2N2O2 360.0 BTK Vassilev J.Biol.Chem. 274 1646 Mahajan et al J.Biol.Chem. 274 9587
LiCl ClLi 42.394 GSK3b Galli C. (2013) Clin Oral Implants Res. 921-7.
LRRK2-IN1 C31H38N8O3 570.69 LRRK2 Deng X. (2011) Nat. Chem. Biol. 7 203
LY294002 C19H17NO3 307.4 PI3K Baumann P. and West S.C. (1998) Proc. Natl. Acad. Sci. USA 95 14066 Cardone M.H. (1998) Science 282 1318
LY333531 (Ruboxistaurin) C28H28IN4O3 .CH4O3S 582.73 PKC Jirousek M.R. (1996) J. Med. Chem. 39 2664 Tang S. (2008) Proteins 72(1) 447-60
LY364947 C17H12N4 272.31 TGF-β type-I Sawyer (2003) J.Med.Chem. 46 3953 Li (2006) J.Med.Chem. 49 2138
Merck 7 (PDK1) C28H22F2N4O4 516.5 PDK1 Nagashima K. (2011) J.Biol.Chem. 286 6433-6448
Metformin C4H11N5 129.16 AMP Ouyang J. (2010) J. Biol. Chem. 2011 Jan. 7 286(1) 1-11
MK-2206 C25H21N5O.2HCl 480.39 PKB Hui-Fang Li (2009) Radiation Oncology 4 43
ML-7, Hydrochloride C15H17IN2O2S • HCl 452.7 MLCK Krarup T. (1998) Am. J. Physiol. 275 C239 Saitoh M. (1987) J. Biol. Chem. 262 7796
ML-9, Hydrochloride C15H17ClN2O2S • HCl 361.3 MLCK Reig J.A. (1993) Neurochem. Res. 18 317 Nagatsu T. (1987) Biochem. Biophys. Res. Commun. 143 1045
MLi-2 C21H25N5O2 LRRK2 Matthew J. Fell (2015) Journal of Pharmacology and Experimental Therapeutics 355(3) 397-409
MLN120B C19H17Cl3N4O2 439.72 IKKb Nagashima K. Fraser C.C. (2006) Blood 107 4266-4273 Catley M.C. Newton R. (2006) Mol.Pharmacol. 70 697-705
MLN4924 C21H26ClN5O4S 479.98 NEDD8-activating enzyme Teresa A. Soucy (2009) Nature 458 732-736
MLN9708 C20H23BCl2N2O9 517.12 Proteasome Kupperman. E. (2010) Cancer Research 70 1970-1980
MRT199665 C28H31N5O2.ClH 506.04 MARK Clark K. (2012) Proc Natl Acad Sci USA 109(42) 16986-91
MRT67307 C26H36N6O2 464.60 IKKε, TBK1 Clark K. (2011) Biochem. J. 434 93-104
MSC 2032964A C16H13F3N6O 362.31 ASK1 Guo X. (2010) EMBO Molecular Medicine 2 504-515
Necrostatin-1 (Nec-1) C13H13N3OS 259.33 RIP Degterev A. Hitomi J. (2008) Nature Chemical Biology 4 313-321
Nectrostatin-1 (Nec-1 inactive analog) C12H11N3OS 245.3 RIP Degterev A. Hitomi J. (2008) Nature Chemical Biology 4 313-321
NG-25 C29H30F3N5O2 537.58 TAK1 Dzamko N (2012) PLoS ONE 7(6) e39132 10 1371 Eduardo Pauls (2012) Journal of Biological Chemistry 287 23 19216-19228
NIK-Novartis-T1-7 C18H14N6OS 362.41 NIK
Novartis 12a (PKD1) C23H29F3N6O3 494.51 PKD1 Meredith E.L. (2010) J.Med.Chem. 53 5422-5438

Pages

XLSCSVXLSCSV

Do you need any help? Please get in touch and we’ll be happy to lend a hand.